August 12, 2008 - American HealthChoice Inc. (AMHI), a medical services company with medical clinics in Texas and Tennessee, said today the FDA approved its OmniBody Scan, an infrared thermal imaging camera that will be able to detect patterns of abnormality within the human body.

In conjunction with existing technologies, the OmniBody Scan will be able to identify problems early enough for prevention and treatment, according to the company.

"Our initial focus will be the worldwide problem of breast cancer,” said Pat McGlashan, president of RehabCo, a division of AMHI. “The dilemma that all women have is that having X-rays to detect breast cancer may cause breast cancer. The OmniBody Scan is a noninvasive tool that will have no harmful side effects. The earlier that breast cancer is detected equates to a much higher chance of survival, especially with Inflammatory Breast Cancer.”

The OmniBody Scan is manufactured specifically for American HealthChoice by an infrared imaging manufacturer. Efforts have begun to solicit resellers to penetrate the U.S. market with both the OmniBody Scan and the company's adjunct support system of providing high quality interpretations of the infrared images, said AMHI.

Five years ago, the U.S. Preventive Services Task Force, an independent panel of experts in primary care and prevention, examined data from numerous clinical trials and estimated that screening mammography every one or two years in women in their 40s resulted in a 15 percent decrease in breast cancer mortality after 14 years of follow-up. But, analyses also made note of the potential harm of screening, including radiation exposure, procedure- associated pain, false-positive results, over-diagnosis and potentially unnecessary treatment.

The OmniBody Scan, a noninvasive technology reportedly with no side effects, is available immediately.

For more information: www.americanhealthchoice.com, www.omnibodyscan.com

Related Content

News | Interventional Radiology

Varian announced it has signed an asset purchase agreement to acquire the Boston Scientific portfolio of drug-loadable microsphere and bland embolic bead products for treating arteriovenous malformations and hypervascular tumors. When completed, this acquisition, in combination with the recent acquisitions of Endocare and Alicon, will expand Varian's portfolio of multidisciplinary integrated cancer care solutions.

Time July 03, 2019
arrow
Technology | Focused Ultrasound Therapy

Insightec announced that the U.S. Food and Drug Administration (FDA) has approved an expansion of the indication of Exablate Neuro to include the treatment of patients with tremor-dominant Parkinson's disease (PD).

Time December 21, 2018
arrow
Videos | Radiation Oncology

Genomics can be used to assess a patient's radiosensitivity, which can be used to increase or decrease the radiation ...

Time November 06, 2018
arrow
News | Radiation Dose Management

AngioDynamics Inc. announced an agreement to acquire RadiaDyne, a privately held medical diagnostic and device company that designs and develops patient dose monitoring technology to improve cancer treatment outcomes.

Time September 24, 2018
arrow
News | Radiation Oncology

World Cancer Day takes place annually on Feb. 4 to raise awareness and education in the media, governments and people ...

Time February 01, 2018
arrow
News | Oncology Related Products

December 19, 2016 — Children’s National Health System and Celsion Corp. announced in November the launch of a clinical ...

Time December 19, 2016
arrow
News | Clinical Decision Support

October 27, 2016 — The National Comprehensive Cancer Network (NCCN) continues to build its library of appropriate use ...

Time October 27, 2016
arrow
News | Ultrasound Imaging

September 12, 2016 — Tiny microbubbles are being used to more effectively identify liver tumors, according to a study ...

Time September 12, 2016
arrow
Feature | Cardio-oncology | Dave Fornell

Cardio-oncology is an emerging field that combines the expertise of both cardiology and oncology to assess and treat ...

Time May 13, 2016
arrow
News | Oncology Related Products

May 6, 2016 — After breast cancer surgery, women are prescribed adjuvant (or follow-up) therapies such as chemotherapy ...

Time May 06, 2016
arrow
Subscribe Now